OrbiMed Reduces Adicet Bio Stake to 8.8% After $1.2M Share Sales
Summary
OrbiMed Advisors, a significant institutional investor, reported selling approximately $1.2 million worth of Adicet Bio shares, reducing its beneficial ownership to 8.8%.
Key Events
-
Significant Stake Reduction
OrbiMed Advisors LLC and its affiliates have reduced their beneficial ownership in Adicet Bio, Inc. to 8.8% of the outstanding common stock.
-
$1.2 Million in Share Sales
The reduction resulted from the sale of 183,158 shares across several transactions on April 7th and 8th, 2026, and a reported sale on April 9, 2025, with total proceeds of approximately $1.2 million.
-
Ongoing Investor Activity
This filing follows recent Form 144 filings from other parties and occurs in the context of Adicet Bio's recent highly dilutive offering and reverse stock split.
Analysis
OrbiMed Advisors LLC and its affiliates, a major institutional investor, have filed an Amendment No. 9 to their Schedule 13D, reporting a reduction in their beneficial ownership of Adicet Bio, Inc. to 8.8% of the outstanding common stock. This decrease follows the sale of 183,158 shares across multiple transactions on April 7th and 8th, 2026, and a historical sale on April 9, 2025, totaling approximately $1.2 million. While institutional investors frequently adjust their holdings, a significant reduction by a major holder can signal a shift in investment sentiment or a need for liquidity. This comes after Adicet Bio's recent highly dilutive offering and reverse stock split, suggesting continued pressure on shareholder value.
At the time of this filing, ACET was trading at $6.60 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $64.9M. The 52-week trading range was $6.01 to $17.44. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.